Trials / Withdrawn
WithdrawnNCT03957161
ACEi ARB Withdrawal in CKD Patients
Angiotensin-converting Enzyme Inhibitors (ACEi) or Angiotensin Receptor Blockers (ARB) Withdrawal in Patients With Advanced Chronic Kidney Disease
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University of California, San Francisco · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The American Heart Association guidelines for high blood pressure (BP) currently recommend using angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) as first-line therapy for patients with chronic kidney disease (CKD) stage 3 or above. However, the prevalence of ACEi and ARB use in patients with CKD stage 4 or 5 is low, and current BP guidelines acknowledge the lack of solid evidence to support the benefit of using these agents in advanced CKD.This study seeks to conduct a pilot trial to determine the safety and feasibility of ACEi and/or ARB continuation (intervention) versus withdrawal (control) in patients with advanced CKD.
Conditions
- Chronic Kidney Disease
- Blood Pressure
- Angiotensin-converting Enzyme Inhibitor
- Angiotensin Receptor Blockers
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Continuation of ACEi and/or ARBs | Patients will continue or start taking ACEi and/or ARBs |
Timeline
- Start date
- 2023-11-01
- Primary completion
- 2023-11-01
- Completion
- 2023-11-01
- First posted
- 2019-05-21
- Last updated
- 2023-11-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03957161. Inclusion in this directory is not an endorsement.